Expertise in
37
conditions

Dr. Raj Vuppalanchi

Gastroenterology
Indiana University Health University Hospital
550 University Blvd, 
Indianapolis, IN 
Offers Telehealth
Expertise in
37
conditions
Indiana University Health University Hospital
550 University Blvd, 
Indianapolis, IN 

Overview

Raj Vuppalanchi is a Gastroenterologist in Indianapolis, Indiana. Dr. Vuppalanchi is highly rated in 37 conditions, according to our data. His top areas of expertise are Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis (NASH), Cirrhosis, Liver Transplant, and Gastric Bypass.

His clinical research consists of co-authoring 166 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Gastroenterology

Licenses

Internal Medicine in IN

Hospital Affiliations

Indiana University Health
Indiana University Health Ball Memorial Hospital
Iu Health West Hospital
Indiana University Health North Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Indiana University Health University Hospital
550 University Blvd, Indianapolis, IN 46202
Other Locations
IU Health Methodist Hospital
1701 Senate Blvd, Indianapolis, IN 46202

Additional Areas of Focus

Dr. Vuppalanchi has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
Enrollment Status: Terminated
Publish Date: December 15, 2025
Intervention Type: Drug
Study Drug: Belapectin
Study Phase: Phase 2/Phase 3
A Prospective, Randomized, Double-Blind, Sham-Controlled, Multi-Center, Pivotal Study to Evaluate the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita® System in Subjects With Type 2 Diabetes With Inadequate Glycemic Control
A Prospective, Randomized, Double-Blind, Sham-Controlled, Multi-Center, Pivotal Study to Evaluate the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita® System in Subjects With Type 2 Diabetes With Inadequate Glycemic Control
Enrollment Status: Suspended
Publish Date: November 13, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Placebo-Controlled, Multi-dose, Phase 2 Study to Determine the Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency (AATD) [SEQUOIA]
A Placebo-Controlled, Multi-dose, Phase 2 Study to Determine the Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency (AATD) [SEQUOIA]
Enrollment Status: Completed
Publish Date: November 04, 2025
Intervention Type: Other, Drug
Study Drug: ARO-AAT
Study Phase: Phase 2
Safety and Efficacy of Ketogenic Diet for Promoting Weight Loss in Obese Individuals With Compensated NASH Cirrhosis
Safety and Efficacy of Ketogenic Diet for Promoting Weight Loss in Obese Individuals With Compensated NASH Cirrhosis
Enrollment Status: Active_not_recruiting
Publish Date: March 10, 2025
Intervention Type: Other
Study Phase: Not Applicable
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 2
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
Evaluation of Pharmacokinetics and Safety of Saroglitazar Magnesium in Participants with Normal Hepatic Function and with Hepatic Impairment, Cholestatic Liver Disease, NASH with Advanced Fibrosis
Evaluation of Pharmacokinetics and Safety of Saroglitazar Magnesium in Participants with Normal Hepatic Function and with Hepatic Impairment, Cholestatic Liver Disease, NASH with Advanced Fibrosis
Enrollment Status: Completed
Publish Date: September 20, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Magnesium in Patients With Primary Biliary Cholangitis (EPICS )
A Phase 2, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Magnesium in Patients With Primary Biliary Cholangitis (EPICS )
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
Enrollment Status: Terminated
Publish Date: March 09, 2023
Intervention Type: Drug
Study Drug: Obeticholic Acid 
Study Phase: Phase 4
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)
Enrollment Status: Completed
Publish Date: September 16, 2020
Intervention Type: Drug
Study Phase: Phase 2
Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants
Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants
Enrollment Status: Completed
Publish Date: November 14, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 10 Less Clinical Trials

166 Total Publications

Inpatient Telehepatology at Community Hospitals: Expanding Access and Comanaging Complex Care.
Inpatient Telehepatology at Community Hospitals: Expanding Access and Comanaging Complex Care.
Journal: NEJM catalyst innovations in care delivery
Published: December 18, 2025
Similar Doctors
Expertise in
27
conditions
Dr. Evan Fogel
Gastroenterology
Expertise in
27
conditions
Dr. Evan Fogel
Gastroenterology

Indiana University Health University Hospital

550 University Blvd, 
Indianapolis, IN 
 (1.2 miles away)
317-278-6997
Languages Spoken:
English
See accepted insurances

Evan Fogel is a Gastroenterologist in Indianapolis, Indiana. Dr. Fogel is highly rated in 27 conditions, according to our data. His top areas of expertise are Hereditary Pancreatitis, Chronic Pancreatitis, Sphincter of Oddi Dysfunction, Endoscopy, and Lithotripsy.

Expertise in
39
conditions
Dr. Douglas Rex
Gastroenterology
Expertise in
39
conditions
Dr. Douglas Rex
Gastroenterology

Indiana University Health University Hospital

550 University Blvd, 
Indianapolis, IN 
 (1.2 miles away)
317-944-8660
Languages Spoken:
English
See accepted insurances

Douglas Rex is a Gastroenterologist in Indianapolis, Indiana. Dr. Rex is highly rated in 39 conditions, according to our data. His top areas of expertise are Colorectal Polyps, Colorectal Cancer, Familial Adenomatous Polyposis, Colonoscopy, and Endoscopy.

Expertise in
28
conditions
Dr. Marwan Ghabril
Gastroenterology
Expertise in
28
conditions
Dr. Marwan Ghabril
Gastroenterology

Indiana University Health University Hospital

550 University Blvd, 
Indianapolis, IN 
 (1.2 miles away)
317-944-8660
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Marwan Ghabril is a Gastroenterologist in Indianapolis, Indiana. Dr. Ghabril is highly rated in 28 conditions, according to our data. His top areas of expertise are Liver Failure, Ascites, Cirrhosis, Liver Transplant, and Endoscopy.

Frequently Asked Questions about Dr. Raj Vuppalanchi

How do I make an appointment with Dr. Raj Vuppalanchi?

You can book an appointment with Dr. Raj Vuppalanchi by calling their office at 317-944-0980. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Raj Vuppalanchi a top-rated expert for Non-Alcoholic Fatty Liver Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Raj Vuppalanchi is classified as an Elite expert for Non-Alcoholic Fatty Liver Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Raj Vuppalanchi specialize in?

While Dr. Raj Vuppalanchi is a Gastroenterology, they have specific expertise in Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis (NASH), and Cirrhosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Raj Vuppalanchi participate in research or clinical trials?

Yes. Dr. Raj Vuppalanchi has published 166 articles and abstracts on conditions like Non-Alcoholic Fatty Liver Disease. You can view a list of Dr. Raj Vuppalanchi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Raj Vuppalanchi accept my insurance?

Dr. Raj Vuppalanchi accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 317-944-0980 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Vuppalanchi's expertise for a condition
ConditionClose
View All 8 Elite Conditions
View All 12 Distinguished Conditions
View All 17 Advanced Conditions
View All 48 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile